Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women.

OBJECTIVE To assess variation in genes that regulate cholesterol metabolism in relation to the natural history of HIV infection. DESIGN Cross-sectional and longitudinal analysis of the Women's Interagency HIV Study. METHODS We examined 2050 single nucleotide polymorphisms (SNPs) in 19 genes known to regulate cholesterol metabolism in relation to HIV viral load and CD4 T-cell levels in a multiracial cohort of 1066 antiretroviral therapy-naive women. RESULTS Six SNPs were associated with both HIV viral load and CD4 T-cell levels at a false discovery rate of 0.01. Bioinformatics tools did not predict functional activity for five SNPs, located in introns of nuclear receptor corepressor 2, retinoid X receptor alpha (RXRA), and tetratricopeptide repeat domain 39B. Rs17111557 located in the 3' untranslated region of proprotein convertase subtilisin/kexin type 9 (PCSK9) putatively affects binding of hsa-miR-548t-5p and hsa-miR-4796-3p, which could regulate PCSK9 expression levels. Interrogation of rs17111557 revealed stronger associations in the subset of women with HIV/hepatitis C virus (HCV) coinfection (n = 408, 38% of women). Rs17111557 was also associated with low-density lipoprotein cholesterol levels in HIV/HCV coinfected (β: -10.4; 95% confidence interval: -17.9, -2.9; P = 0.007), but not in HIV monoinfected (β:1.2; 95% confidence interval: -6.3, 8.6; P = 0.76) women in adjusted analysis. CONCLUSION PCSK9 polymorphism may affect HIV pathogenesis, particularly in HIV/HCV coinfected women. A likely mechanism for this effect is PCSK9-mediated regulation of cholesterol metabolism. Replication in independent cohorts is needed to clarify the generalizability of the observed associations.

[1]  A. Sahebkar,et al.  PCSK9 and infection: A potentially useful or dangerous association? , 2018, Journal of cellular physiology.

[2]  B. Nordestgaard,et al.  Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study , 2017, British Medical Journal.

[3]  K. Anastos,et al.  Human leucocyte antigen class I and II imputation in a multiracial population , 2016, International journal of immunogenetics.

[4]  Szilard Voros,et al.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. , 2016, The New England journal of medicine.

[5]  Dave L Dixon,et al.  A review of PCSK9 inhibition and its effects beyond LDL receptors. , 2016, Journal of clinical lipidology.

[6]  A. Butt,et al.  Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES , 2016, Hepatology.

[7]  N. Seidah New developments in proprotein convertase subtilisin–kexin 9's biology and clinical implications , 2016, Current opinion in lipidology.

[8]  K. Anastos,et al.  Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women , 2016, Journal of acquired immune deficiency syndromes.

[9]  P. Ganz,et al.  HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox” , 2016, Journal of the American Heart Association.

[10]  Ming-Ling Chang Metabolic alterations and hepatitis C: From bench to bedside. , 2016, World journal of gastroenterology.

[11]  K. Shimotohno,et al.  Hepatitis C virus utilizes VLDLR as a novel entry pathway , 2015, Proceedings of the National Academy of Sciences.

[12]  R. Chung,et al.  Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES , 2015, BMC Infectious Diseases.

[13]  D. Goldstein,et al.  Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load , 2015, Proceedings of the National Academy of Sciences.

[14]  M. Hirata,et al.  Impact of 3'UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study. , 2015, International journal of clinical and experimental medicine.

[15]  Ina Hoeschele,et al.  Penalized Multimarker vs. Single-Marker Regression Methods for Genome-Wide Association Studies of Quantitative Traits , 2014, Genetics.

[16]  M. Reilly,et al.  PCSK9 is a critical regulator of the innate immune response and septic shock outcome , 2014, Science Translational Medicine.

[17]  M. Bukrinsky,et al.  Interaction of pathogens with host cholesterol metabolism , 2014, Current opinion in lipidology.

[18]  Phalguni Gupta,et al.  Alterations in Cholesterol Metabolism Restrict HIV-1 Trans Infection in Nonprogressors , 2014, mBio.

[19]  Mehmet Deveci,et al.  mrSNP: Software to detect SNP effects on microRNA binding , 2014, BMC Bioinformatics.

[20]  Yang Du,et al.  rSNPBase: a database for curated regulatory SNPs , 2013, Nucleic Acids Res..

[21]  U. Laufs,et al.  Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. , 2013, Journal of the American College of Cardiology.

[22]  Dai Zhang,et al.  MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs , 2012, BMC Genomics.

[23]  Eurie L. Hong,et al.  Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.

[24]  Hong-Mei Zhang,et al.  Genome‐wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis , 2012, Human mutation.

[25]  Manolis Kellis,et al.  HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants , 2011, Nucleic Acids Res..

[26]  M. Carrington,et al.  Human Leukocyte Antigen Genotype and Risk of HIV Disease Progression before and after Initiation of Antiretroviral Therapy , 2011, Journal of Virology.

[27]  Stephen J O'Brien,et al.  Genetic associations of variants in genes encoding HIV-dependency factors required for HIV-1 infection. , 2010, The Journal of infectious diseases.

[28]  R. C. Rose,et al.  The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.

[29]  D. Weinberger,et al.  MicroSNiPer: a web tool for prediction of SNP effects on putative microRNA targets , 2010, Human mutation.

[30]  David J. McDonald Dendritic Cells and HIV-1 Trans-Infection , 2010, Viruses.

[31]  S. Gummuluru,et al.  PPARγ and LXR Signaling Inhibit Dendritic Cell-Mediated HIV-1 Capture and trans-Infection , 2010, PLoS pathogens.

[32]  K. Shianna,et al.  Host determinants of HIV-1 control in African Americans. , 2010, The Journal of infectious diseases.

[33]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[34]  Jonathan C. Cohen,et al.  Genetic and metabolic determinants of plasma PCSK9 levels. , 2009, The Journal of clinical endocrinology and metabolism.

[35]  A. Prat,et al.  PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression , 2009, Hepatology.

[36]  Jack A. Taylor,et al.  SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies , 2009, Nucleic Acids Res..

[37]  A. Prat,et al.  The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2* , 2008, Journal of Biological Chemistry.

[38]  Hagit Shatkay,et al.  F-SNP: computationally predicted functional SNPs for disease association studies , 2007, Nucleic Acids Res..

[39]  Mardge H. Cohen,et al.  Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens , 2007, Journal of acquired immune deficiency syndromes.

[40]  M. Bukrinsky,et al.  Human immunodeficiency virus impairs reverse cholesterol transport from macrophages , 2006, Retrovirology.

[41]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[42]  A. Landay,et al.  Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. , 2006, The Journal of infectious diseases.

[43]  M. Young,et al.  The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench , 2005, Clinical Diagnostic Laboratory Immunology.

[44]  J. Mullins,et al.  Nef Induces Multiple Genes Involved in Cholesterol Synthesis and Uptake in Human Immunodeficiency Virus Type 1-Infected T Cells , 2005, Journal of Virology.

[45]  Jay D. Horton,et al.  Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver* , 2004, Journal of Biological Chemistry.

[46]  B. Peterlin,et al.  Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  W. Pan Akaike's Information Criterion in Generalized Estimating Equations , 2001, Biometrics.

[48]  R. Greenblatt,et al.  Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. , 2000, American journal of epidemiology.

[49]  R. Gelman,et al.  Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. , 1993, Cytometry.